Filing Details

Accession Number:
0001022079-20-000002
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-03 16:39:20
Reporting Period:
2020-01-02
Accepted Time:
2020-01-03 16:39:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1022079 Quest Diagnostics Inc DGX Services-Medical Laboratories (8071) 161387862
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1599837 E. J. Davis 500 Plaza Drive
Secaucus NJ 07094
Evp, General Diagnostics No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-02 65,681 $71.17 102,215 No 4 M Direct
Common Stock Acquisiton 2020-01-02 77,865 $66.51 180,080 No 4 M Direct
Common Stock Disposition 2020-01-02 58,258 $105.46 121,822 No 4 S Direct
Common Stock Disposition 2020-01-02 7,423 $106.51 114,399 No 4 S Direct
Common Stock Disposition 2020-01-02 69,003 $105.45 45,396 No 4 S Direct
Common Stock Disposition 2020-01-02 8,853 $106.51 36,543 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualifed Stock Option (right to buy) Disposition 2020-01-02 65,681 $71.17 65,681 $71.17
Common Stock Non-Qualifed Stock Option (right to buy) Disposition 2020-01-02 77,865 $66.51 77,865 $66.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-02-23 No 4 M Direct
0 2026-02-25 No 4 M Direct
Footnotes
  1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 26, 2019.
  2. This transaction was executed in multiple trades at prices ranging from $105.00 to $105.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $106.00 to $106.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $105.00 to $106.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This transaction was executed in multiple trades at prices ranging from $106.01 to $106.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. The options vested in three equal annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018.
  7. The options vested in three equal annual installments beginning with the first on February 25, 2017, the second on February 25, 2018 and the final on February 25, 2019.